Treatment of Negative Symptoms in Schizophrenia

Introduction to Guideline Recommendations

The American College of Psychiatry recommends Cariprazin or Aripiprazol as first-line treatment for patients with predominant negative symptoms, if positive symptoms are well-controlled 1
The American Psychiatric Association suggests considering low-dose Amisulprid (50 mg twice daily) for negative symptoms, when positive symptoms are not a primary concern 1, 2

Aripiprazol augmentation improves negative symptoms (standardized mean difference −0.41, 95% CI −0.79 to −0.03, p = 0.036) 1, 3
Low-dose Amisulprid is effective for negative symptoms, especially when positive symptoms are not a primary concern 1, 2

The American Academy of Psychiatry and the Law recommends evaluating and addressing secondary causes of negative symptoms, such as persistent positive symptoms, depressive symptoms, substance abuse, social isolation, medical conditions, and side effects of antipsychotics 1
For patients with well-controlled positive symptoms, consider switching to Cariprazin or Aripiprazol 1
For patients with predominant negative symptoms without positive symptoms, consider low-dose Amisulprid 1

Clozapin should be considered for treatment-resistant cases, if not already prescribed 1
Augmentation with Aripiprazol (5-15 mg/day) shows the most robust data for patients with persistent negative symptoms under Clozapin 1, 3

The American College of Psychiatry recommends cariprazine as a first-line switch option for predominant negative symptoms, with strong evidence from recent 2025 international guidelines 4, 5
The American College of Psychiatry recommends amisulpride at low doses (50 mg twice daily) for predominant negative symptoms, with moderate evidence from meta-analysis of 4 trials with 590 patients 4, 5

If positive symptoms are well-controlled, switch to cariprazine or aripiprazole as first-line options, as recommended by the American Psychiatric Association 4, 5
If positive symptoms are minimal/absent, consider low-dose amisulpride (50 mg twice daily) for negative symptoms, as recommended by the American Psychiatric Association 4, 5

Clozapine and olanzapine have the poorest cardiometabolic profiles and highest anticholinergic burden, which may worsen cognitive symptoms and quality of life, according to the National Institute of Mental Health 5
Consider adjunctive metformin when using olanzapine or clozapine to mitigate metabolic side effects, as recommended by the American Diabetes Association 6, 5
Antidepressant augmentation may provide modest benefit for negative symptoms, even without depression diagnosis, as suggested by the American Psychiatric Association 6, 4